Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | D3L-001 |
Synonyms | |
Therapy Description |
D3L-001 is a bispecific antibody targeting ERBB2 (HER2) and CD47, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 1873). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
D3L-001 | D3L 001|D3L001 | CD47 Antibody 31 HER2 (ERBB2) Antibody 76 | D3L-001 is a bispecific antibody targeting ERBB2 (HER2) and CD47, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 1873). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05957536 | Phase I | D3L-001 | A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors | Recruiting | USA | AUS | 1 |